NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









City Therapeutics

City Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.citytx.com/

Last Round

Series B

Jun 8, 2026

Total Funding Raised

$264.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

City Therapeutics is a biotechnology company that develops next-generation RNA interference (RNAi) therapeutics designed to silence disease-causing genes by targeting and degrading messenger RNA.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

RNA interferenceRNAibiotechnologydrug discoverygene silencingtherapeutic pipelinebiotech startuppreclinical researchclinical stagedrug developmentinvestigational medicineRNA therapeuticsbiopharmaRNAi platformdrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

City Therapeutics Comparables

Compare City Therapeutics with similar companies based on industry and business-model similarity.

City Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sanegene Bio
84%
Atalanta Therapeutics
79%
Suzhou Ribo Life Science Co., Ltd.
78%

City Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJun 8, 2026
Convertible DebtMay 27, 2025
Series AOct 8, 2024

City Therapeutics Investors

Notable investors and investment history

City Therapeutics investors
InvestorRounds
ARCH Venture PartnersSeries B, Series A
Fidelity Management & Research CompanySeries B, Series A
Invus OpportunitiesSeries B
ARCH Venture PartnersSeries A
Viking Global InvestorsSeries B
AN Venture PartnersSeries B, Series A
Casdin CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 8, 2026

    $100M round led by Viking Global Investors and Sofinnova Investments.

  • Oct 8, 2024

    $135M round led by ARCH Venture Partners

City Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

City Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about City Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range79
Year Founded2024
Last FundingJun 8, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.